VU 0360223Negative allosteric modulator at mGlu5 CAS# 1274859-33-4 |
2D Structure
- FLAG tag Peptide
Catalog No.:BCC2562
CAS No.:98849-88-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1274859-33-4 | SDF | Download SDF |
PubChem ID | 45103530 | Appearance | Powder |
Formula | C15H9FN2S | M.Wt | 268.31 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 25 mM in DMSO | ||
Chemical Name | 3-fluoro-5-(2-methyl-1,3-benzothiazol-5-yl)benzonitrile | ||
SMILES | CC1=NC2=C(S1)C=CC(=C2)C3=CC(=CC(=C3)C#N)F | ||
Standard InChIKey | WDHYUBIJZHYUOV-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C15H9FN2S/c1-9-18-14-7-11(2-3-15(14)19-9)12-4-10(8-17)5-13(16)6-12/h2-7H,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent negative allosteric modulator of mGlu5 (IC50 = 61 nM). Displays no activity at mGlu1-4 and mGlu7-8. |
VU 0360223 Dilution Calculator
VU 0360223 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.727 mL | 18.6352 mL | 37.2703 mL | 74.5406 mL | 93.1758 mL |
5 mM | 0.7454 mL | 3.727 mL | 7.4541 mL | 14.9081 mL | 18.6352 mL |
10 mM | 0.3727 mL | 1.8635 mL | 3.727 mL | 7.4541 mL | 9.3176 mL |
50 mM | 0.0745 mL | 0.3727 mL | 0.7454 mL | 1.4908 mL | 1.8635 mL |
100 mM | 0.0373 mL | 0.1864 mL | 0.3727 mL | 0.7454 mL | 0.9318 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Conantokin-T
Catalog No.:BCC5977
CAS No.:127476-26-0
- Calystegine B1
Catalog No.:BCN1882
CAS No.:127414-86-2
- Calystegine B2
Catalog No.:BCN1879
CAS No.:127414-85-1
- Y-26763
Catalog No.:BCC7253
CAS No.:127408-31-5
- Y-27152
Catalog No.:BCC7254
CAS No.:127408-30-4
- Odoroside A
Catalog No.:BCC8224
CAS No.:12738-19-1
- chroman 1
Catalog No.:BCC1480
CAS No.:1273579-40-0
- Coclauril
Catalog No.:BCN6150
CAS No.:127350-68-9
- Rebaudioside G
Catalog No.:BCN7860
CAS No.:127345-21-5
- 2-Chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride
Catalog No.:BCC8569
CAS No.:127337-60-4
- YLF-466D
Catalog No.:BCC4086
CAS No.:1273323-67-3
- PACAP 1-27
Catalog No.:BCC5726
CAS No.:127317-03-7
- CNX1351
Catalog No.:BCC6375
CAS No.:1276105-89-5
- HS-173
Catalog No.:BCC5363
CAS No.:1276110-06-5
- PF-3644022
Catalog No.:BCC6136
CAS No.:1276121-88-0
- Fananserin
Catalog No.:BCC7440
CAS No.:127625-29-0
- Oleficin
Catalog No.:BCN1848
CAS No.:12764-54-4
- Cadherin Peptide, avian
Catalog No.:BCC1018
CAS No.:127650-08-2
- PF-4989216
Catalog No.:BCC6468
CAS No.:1276553-09-3
- 9alpha,11-Dihydroxydrim-7-en-6-one
Catalog No.:BCN7225
CAS No.:127681-58-7
- (2R)-5,7-Dimethoxyflavanone
Catalog No.:BCN7806
CAS No.:1277188-85-8
- Radicicol
Catalog No.:BCC2131
CAS No.:12772-57-5
- SKF 97541
Catalog No.:BCC6626
CAS No.:127729-35-5
- 2'-O-Methylbroussonin A
Catalog No.:BCN7318
CAS No.:127757-13-5
[Lessons learned from the evacuation of the VU University Medical Centre after flooding].[Pubmed:28224872]
Ned Tijdschr Geneeskd. 2017;161:D861.
On 8 September 2015, flooding of the lower floors of the VU University Medical Center in Amsterdam caused serious damage to many vital technical services, such as water and power supplies. The decision was made to completely evacuate the university hospital. This paper describes the chronology and events of that day and shares a number of important lessons that were learned, in order to help readers to optimise crisis organisation in their own institutions. A serious situation or disaster can never be standardised in protocols or manuals; flexibility, improvisation and confidence in one another's expertise and commitment are therefore essential.
(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction.[Pubmed:21927650]
ACS Chem Neurosci. 2011 Aug 17;2(8):471-482.
Glutamate is the major excitatory transmitter in the mammalian CNS, exerting its effects through both ionotropic and metabotropic glutamate receptors. The metabotropic glutamate receptors (mGlus) belong to family C of the G-protein-coupled receptors (GPCRs). The eight mGlus identified to date are classified into three groups based on their structure, preferred signal transduction mechanisms, and pharmacology (Group I: mGlu(1) and mGlu(5); Group II: mGlu(2) and mGlu(3); Group III: mGlu(4), mGlu(6), mGlu(7), and mGlu(8)). Non-competitive antagonists, also known as negative allosteric modulators (NAMs), of mGlu(5) offer potential therapeutic applications in diseases such as pain, anxiety, gastroesophageal reflux disease (GERD), Parkinson's disease (PD), fragile X syndrome, and addiction. The development of SAR in a (3-cyano-5-fluorophenyl)biaryl series using our functional cell-based assay is described in this communication. Further characterization of a selected compound, 3-fluoro-5-(2-methylbenzo[d]thiazol-5-yl)benzonitrile, in additional cell based assays as well as in vitro assays designed to measure its metabolic stability and protein binding indicated its potential utility as an in vivo tool. Subsequent evaluation of the same compound in a pharmacokinetic study using intraperitoneal dosing in mice showed good exposure in both plasma and brain samples. The compound was efficacious in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu(5) antagonists. A new operant model of addiction termed operant sensation seeking (OSS) was chosen as a second behavioral assay. The compound also proved efficacious in the OSS model and constitutes the first reported example of efficacy with a small molecule mGlu(5) NAM in this novel assay.